Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial + +...

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01073-6/abstract?dgcid=raven_jbs_etoc_feature_lancet Editorial +... p665 Reversing the rise of liver cancer The Lancet https://www.thelancet.com/journals/lancet/issue/vol406no10504/PIIS0140-6736(25)X0033-7